|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Anderson WF, Althuis MD, Brinton LA and
Devesa SS: Is male breast cancer similar or different than female
breast cancer? Breast Cancer Res Treat. 83:77–86. 2004.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Thomas DB: Breast cancer in men. Epidemiol
Rev. 15:220–231. 1993.PubMed/NCBI View Article : Google Scholar
|
|
4
|
O'Malley CD, Prehn AW, Shema SJ and Glaser
SL: Racial/ethnic differences in survival rates in a
population-based series of men with breast carcinoma. Cancer.
94:2836–2843. 2002.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Giordano SH, Buzdar AU and Hortobagyi GN:
Breast cancer in men. Ann Intern Med. 137:678–687. 2002.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Cutuli B, Lacroze M, Dilhuydy JM, Velten
M, De Lafontan B, Marchal C, Resbeut M, Graic Y, Campana F and
Moncho-Bernier V: Male breast cancer: Results of the treatments and
prognostic factors in 397 cases. Eur J Cancer. 31A:1960–1964.
1995.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Mabuchi K, Bross DS and Kessler II: Risk
factors for male breast cancer. J Natl Cancer Inst. 74:371–375.
1985.PubMed/NCBI
|
|
8
|
Nahleh ZA, Srikantiah R, Safa M, Jazieh
AR, Muhleman A and Komrokji R: Male breast cancer in the veterans
affairs population: A comparative analysis. Cancer. 109:1471–1477.
2007.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Giordano SH, Cohen DS, Buzdar AU, Perkins
G and Hortobagyi GN: Breast carcinoma in men: A population-based
study. Cancer. 101:51–57. 2004.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ferzoco RM and Ruddy KJ: The epidemiology
of male breast cancer. Curr Oncol Rep. 18(1)2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ewertz M, Holmberg L, Tretli S, Pedersen
BV and Kristensen A: Risk factors for male breast cancer-a
case-control study from scandinavia. Acta Oncol. 40:467–471.
2001.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Rosenblatt KA, Thomas DB, McTiernan A,
Austin MA, Stalsberg H, Stemhagen A, Thompson WD, Curnen MG,
Satariano W and Austin DF: Breast cancer in men: Aspects of
familial aggregation. J Natl Cancer Inst. 83:849–854.
1991.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Casagrande JT, Hanisch R, Pike MC, Ross
RK, Brown JB and Henderson BE: A case-control study of male breast
cancer. Cancer Res. 48:1326–1330. 1988.PubMed/NCBI
|
|
14
|
Basham VM, Lipscombe JM, Ward JM, Gayther
SA, Ponder BA, Easton DF and Pharoah PD: BRCA1 and BRCA2 mutations
in a population-based study of male breast cancer. Breast Cancer
Res BCR. 4(R2)2002.PubMed/NCBI View
Article : Google Scholar
|
|
15
|
Couch FJ, Farid LM, DeShano ML, Tavtigian
SV, Calzone K, Campeau L, Peng Y, Bogden B, Chen Q, Neuhausen S, et
al: BRCA2 germline mutations in male breast cancer cases and breast
cancer families. Nat Genet. 13:123–125. 1996.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Friedman LS, Gayther SA, Kurosaki T,
Gordon D, Noble B, Casey G, Ponder BA and Anton-Culver H: Mutation
analysis of BRCA1 and BRCA2 in a male breast cancer population. Am
J Hum Genet. 60:313–319. 1997.PubMed/NCBI
|
|
17
|
Ottini L, Masala G, D'Amico C, Mancini B,
Saieva C, Aceto G, Gestri D, Vezzosi V, Falchetti M, De Marco M, et
al: BRCA1 and BRCA2 mutation status and tumor characteristics in
male breast cancer: A population-based study in italy. Cancer Res.
63:342–347. 2003.PubMed/NCBI
|
|
18
|
Sverdlov RS, Barshack I, Bar Sade RB,
Baruch RG, Hirsh-Yehezkel G, Dagan E, Feinmesser M, Figer A and
Friedman E: Genetic analyses of male breast cancer in israel. Genet
Test. 4:313–327. 2000.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ding YC, Steele L, Kuan CJ, Greilac S and
Neuhausen SL: Mutations in BRCA2 and PALB2 in male breast cancer
cases from the United States. Breast Cancer Res Treat. 126:771–778.
2011.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Silvestri V, Rizzolo P, Zanna I, Falchetti
M, Masala G, Bianchi S, Papi L, Giannini G, Palli D and Ottini L:
PALB2 mutations in male breast cancer: A population-based study in
central italy. Breast Cancer Res Treat. 122:299–301.
2010.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Boyd J, Rhei E, Federici MG, Borgen PI,
Watson P, Franklin B, Karr B, Lynch J, Lemon SJ and Lynch HT: Male
breast cancer in the hereditary nonpolyposis colorectal cancer
syndrome. Breast Cancer Res Treat. 53:87–91. 1999.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Fry DW, Harvey PJ, Keller PR, Elliott WL,
Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK and
Toogood PL: Specific inhibition of cyclin-dependent kinase 4/6 by
PD 0332991 and associated antitumor activity in human tumor
xenografts. Mol Cancer Ther. 3:1427–1438. 2004.PubMed/NCBI
|
|
23
|
Cardoso F, Bartlett JMS, Slaets L, van
Deurzen CHM, van Leeuwen-Stok E, Porter P, Linderholm B, Hedenfalk
I, Schröder C, Martens J, et al: Characterization of male breast
cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG international
male breast cancer program. Ann Oncol. 29:405–417. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Cardoso F, Costa A, Senkus E, Aapro M,
André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso
MJ, et al: 3rd ESO-ESMO international consensus guidelines for
advanced breast cancer (ABC 3). Ann Oncol. 28:16–23.
2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sharif MA, Mamoon N, Arif A and Khadim MT:
Histological and immuno-histochemical study of male breast
carcinoma in northern Pakistan. J Pak Med Assoc. 59:67–71.
2009.PubMed/NCBI
|
|
26
|
Fox SB, Rogers S, Day CA and Underwood JC:
Oestrogen receptor and epidermal growth factor receptor expression
in male breast carcinoma. J Pathol. 166:13–18. 1992.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Arslan UY, Oksüzoğlu B, Ozdemir N, Aksoy
S, Alkış N, Gök A, Kaplan MA, Gümüş M, Berk V, Uncu D, et al:
Outcome of non-metastatic male breast cancer: 118 patients. Med
Oncol. 29:554–560. 2012.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Moore J, Friedman MI, Gansler T, Gramlich
TL, Derose PB, Hunt D and Cohen C: Prognostic indicators in male
breast carcinoma. Breast J. 4:261–269. 1998.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Leach IH, Ellis IO and Elston CW:
C-erb-B-2 expression in male breast carcinoma. J Clin Pathol.
45(942)1992.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Willsher PC, Leach IH, Ellis IO, Bell JA,
Elston CW, Bourke JB, Blamey RW and Robertson JF: Male breast
cancer: Pathological and immunohistochemical features. Anticancer
Res. 17:2335–2338. 1997.PubMed/NCBI
|
|
31
|
Giordano SH: A review of the diagnosis and
management of male breast cancer. Oncologist. 10:471–479.
2005.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Gradishar WJ, Anderson BO, Balassanian R,
Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A,
Giordano SH, et al: Invasive breast cancer version 1.2016, NCCN
clinical practice guidelines in oncology. J Natl Compr Canc Netw.
14:324–354. 2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
White J, Kearins O, Dodwell D, Horgan K,
Hanby AM and Speirs V: Male breast carcinoma: Increased awareness
needed. Breast Cancer Res. 13(219)2011.
|
|
34
|
Labrie F, Dupont A, Belanger A,
Lacourcière Y, Béland L, Cusan L and Lachance R: Complete response
to combination therapy with an LHRH agonist and flutamide in
metastatic male breast cancer: A case report. Clin Invest Med.
13:275–278. 1990.PubMed/NCBI
|
|
35
|
Lopez M, Natali M, Di Lauro L, Vici P,
Pignatti F and Carpano S: Combined treatment with buserelin and
cyproterone acetate in metastatic male breast cancer. Cancer.
72:502–505. 1993.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Doberauer C, Niederle N and Schmidt CG:
Advanced male breast cancer treatment with the LH-RH analogue
buserelin alone or in combination with the antiandrogen flutamide.
Cancer. 62:474–478. 1988.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zagouri F, Sergentanis TN, Azim HA Jr,
Chrysikos D, Dimopoulos MA and Psaltopoulou T: Aromatase inhibitors
in male breast cancer: A pooled analysis. Breast Cancer Res Treat.
151:141–147. 2015.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Zagouri F, Sergentanis TN, Chrysikos D,
Dimopoulos MA and Psaltopoulou T: Fulvestrant and male breast
cancer: A pooled analysis. Breast Cancer Res Treat. 149:269–275.
2015.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Lumachi F, Luisetto G, Basso SM and
Camozzi V: Endocrine therapy of breast cancer. Curr Med Chem.
18:513–522. 2011.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Finn RS, Aleshin A and Slamon DJ:
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen
receptor-positive breast cancers. Breast Cancer Res.
18(17)2016.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Lundberg AS and Weinberg RA: Functional
inactivation of the retinoblastoma protein requires sequential
modification by at least two distinct cyclin-cdk complexes. Mol
Cell Biol. 18:753–761. 1998.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Malumbres M: Cyclin-dependent kinases.
Genome Biol. 15(122)2014.PubMed/NCBI View
Article : Google Scholar
|
|
43
|
Gelbert LM, Cai S, Lin X, Sanchez-Martinez
C, Del Prado M, Lallena MJ, Torres R, Ajamie RT, Wishart GN, Flack
RS, et al: Preclinical characterization of the CDK4/6 inhibitor
LY2835219: In vivo cell cycle-dependent/independent anti-tumor
activities alone/in combination with gemcitabine. Invest New Drugs.
32:825–837. 2014.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Puyol M, Martin A, Dubus P, Mulero F,
Pizcueta P, Khan G, Guerra C, Santamaria D and Barbacid M: A
synthetic lethal interaction between K-Ras oncogenes and Cdk4
unveils a therapeutic strategy for non-small cell lung carcinoma.
Cancer Cell. 18:63–73. 2010.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Baker SJ and Reddy EP: CDK4: A key player
in the cell cycle, development, and cancer. Genes Cancer.
3:658–669. 2012.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Dean JL, McClendon AK, Hickey TE, Butler
LM, Tilley WD, Witkiewicz AK and Knudsen ES: Therapeutic response
to CDK4/6 inhibition in breast cancer defined by ex vivo analysis
of human tumors. Cell Cycle. 11:2756–2761. 2012.PubMed/NCBI View
Article : Google Scholar
|
|
47
|
Finn RS, Crown JP, Lang I, Boer K,
Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, et
al: The cyclin-dependent kinase 4/6 inhibitor palbociclib in
combination with letrozole versus letrozole alone as first-line
treatment of estrogen receptor-positive, HER2-negative, advanced
breast cancer (PALOMA-1/TRIO-18): A randomized phase 2 study.
Lancet Oncol. 16:25–35. 2015.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Finn RS, Martin M, Rugo HS, Jones SE, Im
SA, Gelmon KA, Harbeck N, Lipatov ON and Walshe JM and Walshe JM:
PALOMA-2: Primary results from a phase III trial of palbociclib (P)
with letrozole (L) compared with letrozole alone in postmenopausal
women with ER+/HER2-advanced breast cancer. J Clin
Oncol. May 11, 2017 (Epub ahead of print). doi:
10.1200/JCO.2016.34.15_suppl.507. View Article : Google Scholar
|
|
49
|
Turner NC, Ro J, Andre F, Loi S, Verma S,
Harbeck HI, Loibl S, Bartlett CH, Zhang K and Giorgetti C, et al:
PALOMA3: A double-blind, phase III trial of fulvestrant with or
without palbociclib in pre- and post-menopausal women with hormone
receptor-positive, HER2-negative metastatic breast cancer that
progressed on prior endocrine therapy. J Clin Oncol. Jan 31, 2017
(Epub ahead of print). doi: 10.1200/jco.2015.33.18_suppl.lba502.
PubMed/NCBI View Article : Google Scholar
|
|
50
|
Lallena MJ, Boehnke K, Torres R, Hermoso
A, Amat J, Calsina B, De Dios A, Buchanan S, Du J, Beckmann RP, et
al: In-vitro characterization of Abemaciclib pharmacology in
ER+ breast cancer cell lines. Presented at Proceedings
of the 106th Annual Meeting of the American Association for Cancer
Research (AACR) Congress. (abstract 3101). 2015.doi:
10.1158/1538-7445.AM2015-3101. View Article : Google Scholar
|
|
51
|
Fujiwara Y, Tamura K, Kondo S, Tanabe Y,
Iwasa S, Shimomura A, Kitano S, Ogasawara K, Turner PK and Mori J:
Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as
single agent for Japanese patients with advanced cancer. Cancer
Chemother Pharmacol. 78:281–288. 2016.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Patnaik A, Tolaney SM, Tolcher AW, Goldman
JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, Nasir
A, et al: Efficacy and safety of abemaciclib, an inhibitor of CDK4
and CDK6, for patients with breast cancer, non-small cell lung
cancer, and other solid tumors. Cancer Discov. 6:740–753.
2016.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Dickler MN, Tolaney SM, Rugo HS, Cortés J,
Diéras V, Patt D, Wildiers H, Hudis CA, O'Shaughnessy J, Zamora E,
et al: MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6
inhibitor, as a single agent, in patients with refractory
HR+/HER2- metastatic breast cancer. Clin
Cancer Res. 23:5218–5224. 2018.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Sledge GW Jr, Toi M, Neven P, Sohn J,
Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, et al:
Monarch 2: Abemaciclib in combination with fulvestrant in women
with HR+/HER2- advanced breast cancer who had
progressed while receiving endocrine therapy. J Clin Oncol.
1:2875–2884. 2017.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Sorscher S: A first case of male breast
cancer responding to combined aromatase inhibitor/palbociclib
therapy. Int J Cancer Clin Res. Oct 19, 2016 (Epub ahead of print).
View Article : Google Scholar
|
|
56
|
Castrellon AB, Nguyen SM, Milillo Naraine
AM, Velez M and Raez LE: Initial response to therapy with
fulvestrant and cyclin-dependent kinase 4/6 inhibitor in a male
with stage IV breast cancer. Mathews J Cancer Sci. Mar 1, 2017
(Epub ahead of print).
|
|
57
|
Gong X, Litchfield LM, Webster Y, Chio LC,
Wong SS, Stewart TR, Dowless M, Dempsey J, Zeng Y, Torres R, et al:
Genomic aberrations that activate D-type cyclins are associated
with enhanced sensitivity to the CDK4 and CDK6 inhibitor
abemaciclib. Cancer Cell. 32:761–776. 2017.PubMed/NCBI View Article : Google Scholar
|
|
58
|
DeMichele A, Clark AS, Tan KS, Heitjan DF,
Gramlich K, Gallagher M, Lal P, Feldman M, Zhang P, Colameco C, et
al: CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+
advanced breast cancer: Phase II activity, safety, and predictive
biomarker assessment. Clin Cancer Res. 21:995–1001. 2015.PubMed/NCBI View Article : Google Scholar
|
